


In the Claims:

Please cancel claims 10-12 and 14. Please amend claims 1-9, and 13 as follows. Please add new claims 15-20.

Claims are amended herein.

1. (Currently Amended) A compound of formula (I)



R represents is halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;

R₁ represents is hydrogen, halogen, C₃₋₇cycloalkyl, hydroxy, nitro, cyano or C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy;

R₂ represents is hydrogen or C₁₋₄ alkyl;

R₃ and R₄ independently represents are hydrogen, cyano, C₁₋₄ alkyl or R₃ together with R₄ and the carbon to which they are bonded form a represents C₃₋₇ cycloalkyl;

R₅ represents is trifluoromethyl, S(O)_t C₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy, halogen or cyano;

R₆ represents is hydrogen or (CH₂)_rR₇;

R₇ represents is hydrogen, C₃₋₇ cycloalkyl, NH(C₁₋₄alkyl)OC₁₋₄alkoxy), NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)NR₉R₈, NR₈C(O)5R₉ or C(O)NR₉R₈;

R₉ and R₈ independently represents are hydrogen, C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m represents is zero or an integer from 1 to 4;

n represents is 1 or 2;

p is zero or an integer from 1 to 3;

q is an integer from 1 to 3;

r is an integer from 1 to 4;

t is 0, 1 or 2;

provided that when m is 0, p is 2, q, r and n ~~represents~~ is 1, R₁, R₂, R₃, R₄,

R₅ and R₇ are hydrogen and R is chlorine, then R₅ is not iodine;
and or a pharmaceutically acceptable salt or solvate salts and solvates
thereof.

2 (Currently Amended) A compound as claimed in claim 1 wherein R is halogen (~~e.g. fluorine or chlorine~~), cyano, trifluoromethyl or a C₁₋₄ alkyl (~~e.g. methyl~~) group and p is 0 or an integer from 1 to 2.

3. (Currently Amended) A compound as claimed in claim 1 claims 1
~~er-2~~ wherein R₅ is trifluoromethyl, cyano, methyl or halogen and q is an integer from 1 to 2.

4. (Currently Amended) A compound as claimed in claim 1 any
~~claims 1 to 3~~ wherein R₆ is hydrogen or (CH₂)_rR₇ in which r is 1 or 2 and R₇ is hydrogen, cyclopropyl, C(O)N(C₁₋₄ alkyl)₂, C(O)NH(C₁₋₄ alkyl) or C₁₋₄ alkoxy.

5. (Currently Amended) A compound as claimed in claim 1 any
~~claims 1 to 4~~ wherein R is C₁₋₄ alkyl, halogen (~~i.e. chlorine or fluorine~~), trifluoromethyl or cyano; R₁ is hydrogen, methyl, ethyl or halogen (~~e.g. fluorine~~), R₂ is a methyl or hydrogen, R₃ and R₄ are independently hydrogen or methyl, R₅ is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R₆ is hydrogen, methyl, ethyl methylcyclopropyl (CH₂)₂OCH₃ or CH₂C(O)N(CH₃)₂, p is 0 or an integer from 1 to 2, m is 0 or 1, n is 1 or 2, and q is 1 or 2.

6. (Currently Amended) A compound as claimed in claim 1 any
~~claims 1 to 5~~ wherein m is 1.

7. (Currently Amended) A compound selected from:

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide ;

4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;

N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-[2-(methyloxy)ethyl]-4-piperidinyl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]acetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]acetamide;

N-(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-{[3,5-Bis(trifluoromethyl)phenyl]methyl}-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-*N*-methyl-acetamide ;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;

2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-*N*[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;
2-[4-{2-[(3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(4-fluorophenyl)-1-piperidinyl]-*N,N*-dimethylacetamide;
N[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
N{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
N{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
N[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
N[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;
N[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
N[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
N[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;
N[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;
N[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidinyl]-*N*-methylacetamide;
N[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
N[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;
N[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide ;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

N-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide ;


N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;


N[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;
N[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;
2-[4-(4-Cyanophenyl)-4-piperidinyl]-*N*[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;
diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts (e.g. hydrochloride) thereof.

8 (Currently Amended) A compound selected from
[N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;
N[1-(*S*)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide;
N[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide (enantiomer 1);
N[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-*N*-methyl-acetamide (enantiomer 1);
N[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-*N*-methyl-acetamide (enantiomer 1);
and pharmaceutically acceptable salts thereof (e.g. hydrochloride).

9. (Currently Amended) A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R₆ is a nitrogen protecting group or (CH₂)_rR₇, with amine (III)



wherein R_2 is hydrogen, C₁₋₄ alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group; or a process B for the preparation of a compound of formula (I) wherein R_2 is C₁₋₄ alkyl which comprises the reaction of a compound of formula (Ia), with (C₁₋₄ alkyl)L wherein L is a suitable leaving group selected from iodine, bromine.



10-12. (Canceled)


13. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any claims 1 to 8~~ in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. (Canceled)

15. (New) A compound as claimed in claim 1 wherein R is fluorine or chlorine, cyano, trifluoromethyl or methyl and p is 0 or an integer from 1 to 2.

16. (New) A compound as claimed in claim 1 wherein R is C₁₋₄ alkyl , chlorine or fluorine, trifluoromethyl or cyano; R₁ is hydrogen, methyl, ethyl or fluorine, R₂ is a methyl or hydrogen, R₃ and R₄ are independently hydrogen or methyl, R₅ is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R₆ is hydrogen, methyl, ethyl methylcyclopropyl (CH₂)₂OCH₃ or CH₂C(O)N(CH₃)₂, p is 0 or an integer from 1 to 2, m is 0 or 1, n is 1 or 2, and q is 1 or 2.

17. (New) A process (B) for the preparation of a compound as claimed in claim 1 wherein R₂ is C₁₋₄ alkyl comprising reacting a compound of formula(Ia), with (C₁₋₄ alkyl)L wherein L is a suitable leaving group selected from iodine, bromine



18. (New) A method for the treatment of a condition mediated by a tachykinin and/or selective inhibition of serotonin reuptake transporter protein in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.

19. (New) The method as claimed in claim 18, wherein said tachykinin is substance P.

20. (New) The method as claimed in claim 18, wherein said mammal is man.